Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2010
09/30/2010US20100249107 Biomarkers for Alzheimer's Disease Progression
09/30/2010US20100249106 Methods of Making and Using Therapeutically Active Thiophenepyrimidinone Compounds
09/30/2010US20100249105 Indole and indoline derivatives and methods of use thereof
09/30/2010US20100249104 Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
09/30/2010US20100249103 combination treatment
09/30/2010US20100249102 Heterotricyclic Metalloprotease Inhibitors
09/30/2010US20100249101 Malonamide derivatives with antithrombotic activity
09/30/2010US20100249100 Quinazolines useful as modulators of ion channels
09/30/2010US20100249099 Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
09/30/2010US20100249098 Oxypiperidine derivatives and methods of use thereof
09/30/2010US20100249097 Novel substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments
09/30/2010US20100249096 Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases
09/30/2010US20100249095 Substituted Spiro-amide Compounds
09/30/2010US20100249094 Compounds for the Treatment of Hepatitis C
09/30/2010US20100249093 Substituted Heteroarylpiperidine Derivatives As Melanocortin-4 Receptor Modulators
09/30/2010US20100249092 Heteroaryl compounds and uses thereof
09/30/2010US20100249091 Amide Compounds Useful in Therapy
09/30/2010US20100249090 Neurotherapeutic composition and method therefor
09/30/2010US20100249089 Abcg2 inhibitor
09/30/2010US20100249088 Azolecarboxamide compound or salt thereof
09/30/2010US20100249087 Compounds as cannabinoid receptor ligands
09/30/2010US20100249086 Compounds As Cannabinoid Receptor Ligands
09/30/2010US20100249085 Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
09/30/2010US20100249084 Substituted pyrimidines as adenosine receptor antagonists
09/30/2010US20100249083 16,17-carbocyclic condensed steroid compounds having selective estrogenic activity
09/30/2010US20100249082 Modulators of hypoxia inducible factor-1 and related uses
09/30/2010US20100249081 Compositions and methods for treatment of renal disease
09/30/2010US20100249080 Personal care composition
09/30/2010US20100249079 Analogues of cilostazol
09/30/2010US20100249078 Tetracyclic inhibitors of fatty acid amide hydrolase
09/30/2010US20100249076 Prodrugs of 9-aminomethyl tetracycline compounds
09/30/2010US20100249075 Substituted tetralins as selective estrogen receptor-beta agonists
09/30/2010US20100249074 Benzyl-cycloalkyl sphingosine 1-phosphate receptor modulators
09/30/2010US20100249073 Prophylactic and therapeutic treatment of Alzheimer's disease using phytic acid and phytate to reduce amyloid beta plaque and tau protein
09/30/2010US20100249071 Modulators of S1P and Methods of Making And Using
09/30/2010US20100249069 S1p3 receptor inhibitors for treating pain
09/30/2010US20100249068 Substituted nucleoside and nucleotide analogs
09/30/2010US20100249067 Modulators of Mitotic Kinases
09/30/2010US20100249066 Methods of modulating inflammatory cell recruitment and gene expression using haloaryl substituted aminopurines
09/30/2010US20100249065 Biomarkers for Assessing Peripheral Neuropathy Response to Cancer Treatment
09/30/2010US20100249064 Methods and compositions for treating diseases and conditions involving higher molecular weight hyaluronan
09/30/2010US20100249063 Amorphous body composed of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same
09/30/2010US20100249062 Ophthalmic composition
09/30/2010US20100249061 Oligosaccharides, preparation method and use thereof, and pharmaceutical compositions containing same
09/30/2010US20100249060 Topical formulation of low level clobetasol propionate for treating disorders of the skin and mucous membranes
09/30/2010US20100249059 Bone filling complex and method for fabricating the same
09/30/2010US20100249058 Feed additive and feed
09/30/2010US20100249057 Trehalose compound and pharmaceutical comprising the compound
09/30/2010US20100249056 Metabolically Stable Alkoxyalkyl Esters of Antiviral or Antiproliferative Phosphonates, Nucleoside Phosphonates and Nucleoside Phosphates
09/30/2010US20100249055 Clofarabine phospholipid derivatives
09/30/2010US20100249054 Purine nucleoside derivative modified in 8-position and medical use thereof
09/30/2010US20100249053 Method for inducing hepatocyte proliferation and uses thereof
09/30/2010US20100249052 Dsrna compositions and methods for treating hpv infections
09/30/2010US20100249051 Bioactive Molecules from Co-Cultivation of Microbes
09/30/2010US20100249050 Epothilone glycoside and use thereof
09/30/2010US20100249049 Arylalkylamine compound and process for preparing the same
09/30/2010US20100249048 Beta glycolipids for the treatment of calcification related degenerative disorders
09/30/2010US20100249047 N-acetyl mannosamine as a therapeutic agent
09/30/2010US20100249046 Novel mangiferin calcium salts, the method for its preparation and its use
09/30/2010US20100249045 Multimodal Abuse Resistant and Extended Release Opioid Formulations
09/30/2010US20100249038 Antagonists of the receptor for advanced glycation end-products (rage)
09/30/2010US20100249035 Peptides, compositions and uses thereof
09/30/2010US20100249034 Gfralpha3 and its uses
09/30/2010US20100249030 Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment
09/30/2010US20100249024 Cetp inhibitors
09/30/2010US20100249015 Use of VEGF in the Treatment of Retarded Fetal Growth in Pregnancy
09/30/2010US20100248336 Methods for purifying nucleic acids
09/30/2010US20100248282 DETECTION OF NO BY USING GUANYLYL CYCLASE AND cGMP PRODUCTION AS A READOUT SYSTEM
09/30/2010US20100248241 Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571
09/30/2010US20100248240 Gene and protein relating to hepatocellular carcinoma and methods of use thereof
09/30/2010US20100247734 Methods for Making Nutritional Compositions Comprising Curcuminoids
09/30/2010US20100247694 Composition and method for treament of inflamation and infections of the outer ear canal, nose and paranasal sinuses
09/30/2010US20100247692 Cholesterol Sulfate And Amino Sugar Compositions For Enhancement Of Stratum Corneum Function
09/30/2010US20100247688 Pirenzepine and derivatives thereof as anti-amyloid agents
09/30/2010US20100247682 Use of nitrite salts for the treatment of cardiovascular conditions
09/30/2010US20100247669 Polymer-agent conjugates, particles, compositions, and related methods of use
09/30/2010US20100247664 Method of preventing or treating metabolic syndrome
09/30/2010US20100247663 Microspheres
09/30/2010US20100247662 Biologic Modulations with Nanoparticles
09/30/2010US20100247659 Phenylphthalimide analogs for treating diabetic macular edema
09/30/2010US20100247658 Organic compounds
09/30/2010US20100247657 Telomerase reverse transcriptase variant
09/30/2010US20100247654 Stable micelles formed with diblock copolymers of critical micelle concentration copolymer and temperature-sensitive copolymer
09/30/2010US20100247653 Nanoparticles containing nicotine and/or cotinine, dispersions, and use thereof
09/30/2010US20100247652 Alginate Biomaterials for the Treatment of Hepatic Disorders
09/30/2010US20100247649 Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
09/30/2010US20100247647 Sustained release tablets with hydromorphone
09/30/2010US20100247646 Extended release tablets of nisoldipine
09/30/2010US20100247645 Pharmaceutical combination of aliskiren and valsartan
09/30/2010US20100247644 Adhesive compositions for the treatment of xerostomia
09/30/2010US20100247643 Oral formulations
09/30/2010US20100247642 Stable pharmaceutical formulation for a dpp-iv inhibitor
09/30/2010US20100247640 Solid Oral Dosage Form Containing An Enhancer
09/30/2010US20100247639 Coated pharmaceutical or nutraceutical preparation with enhanced active substance release in the colon
09/30/2010US20100247637 Compositions and pharmaceutical forms for the oral administration of thyroid hormones able to combat the action of sequestrants in the gastrointestinal tract
09/30/2010US20100247636 Nanoparticulate and controlled release compositions comprising nilvadipine
09/30/2010US20100247635 Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
09/30/2010US20100247634 Compositions and Methods for Inhibiting Gastric Acid Secretion
09/30/2010US20100247632 Stabilized solubility-enhanced formulations for oral delivery
09/30/2010US20100247631 Preparations for the external application of antiseptic agents and/or agents promoting the healing of wounds